By Here is a list of the top 10 Healthcare IoT Stocks to invest in and look out for in April 2022
The Internet of Medical Things (IoMT) is rapidly gaining traction as healthcare organizations seek new methods to innovate and stay current with technology in order to help patients and clinicians better monitor and track ailments. The Internet of Things (IoT) has grown rapidly in healthcare in recent years, and the pandemic has accelerated the emergence of IoMT, which several governments have widely used as a strategy to prevent the virus’s spread. The industry has one of the greatest rates of IoT investment and growth.
A 2020 FICCI-BCG report states that: “Health tracking devices and electronic health records combined with AI and Machine Learning (ML) technologies will not only pave the way for efficient chronic disease management but will also lead to the emergence of efficient clinical decision support systems.”
1. Softeq creates IoT healthcare devicesas well as the software that supports them, including operating systems, controllers, cloud-based data analytics tools, medical equipment interfaces, and mobile apps.
2. Boston Scientific has launched the MODULAR ATP clinical study to evaluate the mCRM Modular Therapy System’s safety, performance, and efficacy. The EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD) System as well as the EMPOWER Modular Pacing System (MPS), which is planned to be the first leadless pacemaker capable of providing both bradycardia pacing support and anti-tachycardia pacing, make up the mCRM System.
3. Medtronic is yet another business with a strong presence in the IoMT space. Medtronic announced in October 2021 that the Hugo robotic-assisted surgery (RAS) system has received the CE Mark, allowing it to be sold in Europe.
4. DexCom is a diabetes management company that specializes in medical devices that monitor blood glucose levels continuously. The G6 system from the business consists of an auto-applicator, a sensor & transmitter, and a touch screen receiver that displays real-time glucose data. DexCom has gained FDA approval for two critical software solutions which will enable the company’s linked ecosystem to grow. The DexCom real-time API is the first, and it allows third-party developers to integrate real-time CGM readings into their digital health applications and devices. The second is the company’s app-in-app module, which interfaces directly with third-party healthcare applications, making Type 2 Non-intensive insulin treatment (NIIT) patients’ diabetes management easier.
5. RxDataScience, a healthcare-focused data analytics, data management, and artificial intelligence (AI) startup, was recently acquired by Syneos Health. Syneos Health’s portfolio now includes AI and data engineering capabilities, enterprise analytics, and technology-enabled solutions as a result of the purchase. Customer strategies will be generated by combining the company’s end-to-end services and strong behavioral and therapeutic experience with RxDataScience’s AI and data-science capabilities to enhance product development.
6. In mid-September, Teva Pharmaceutical Industries Ltd announced a collaboration with Intel CorporationINTC to create a wearable device & machine learning platform for Huntington’s disease (HD).
7. Qualcomm Incorporated has inked a contract with Boehringer Ingelheim through its subsidiary Qualcomm Life, Inc., in which the two firms would collaborate to improve chronic obstructive pulmonary disease (COPD) care.
8. GlaxoSmithKline plc, a British pharmaceutical corporation, is forming Galvani Bioelectronics in cooperation with Verily to create bioelectronic treatments. Bioelectronic medicine is a relatively new scientific discipline that involves the use of small, implanted devices to alter electrical signals that run along nerves, including irregular or altered impulses that occur in a variety of disorders.
9. Novartis AG, a Swiss pharma giant, will supply a technological solution for the interconnectivity of the next generation of Novartis’ Breezhaler, a COPD therapy device.
10. Sanofi formed a joint venture partnering with Verily Life Sciences, an Alphabet subsidiary, to create holistic solutions that integrate devices, software, medicines, and professional care to enable easy and intelligent treatment strategies for diabetics.
